StemRIM Completes Enrollment in Early-Stage Redasemtide Trial for Ischemic Cardiomyopathy

StemRIM Inc. ( (JP:4599) ) has shared an update.

StemRIM Inc. said it has completed patient enrollment in a Phase 1/2 investigator-initiated clinical trial of its regeneration-inducing drug candidate redasemtide in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting. Conducted at five institutions led by Osaka University Hospital, the study enrolled 14 patients instead of the initially planned 20, after investigators judged this number sufficient to evaluate the primary endpoints of safety and tolerability.

Redasemtide or placebo was administered for five days, and secondary endpoints will assess cardiac function 52 weeks after dosing, providing early efficacy signals in this high-need cardiovascular indication. The company noted that the trial, for which rights have been licensed to Shionogi & Co., currently has no impact on its consolidated financial results for the fiscal year ending July 2026, but successful safety data could strengthen StemRIM’s positioning in regenerative therapeutics and support future development and partnering steps.

More about StemRIM Inc.

StemRIM Inc., a biotechnology venture originating from Osaka University, is developing a new class of “Regeneration-Inducing Medicine” designed to trigger the body’s own tissue repair mechanisms through drug administration rather than cell or tissue transplants. Its leading candidates work by mobilizing mesenchymal stem cells from bone marrow into peripheral blood, aiming to treat a wide range of conditions including cardiomyopathy, osteoarthritis, cerebral infarction, chronic liver disease, pulmonary fibrosis, and other disorders where ectomesenchymal stem cell therapy is considered promising.

Average Trading Volume: 180,588

Technical Sentiment Signal: Sell

Current Market Cap: Yen19.31B

Learn more about 4599 stock on TipRanks’ Stock Analysis page.